Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis
Received 19 October 2018
Accepted for publication 7 December 2018
Published 27 December 2018 Volume 2019:15 Pages 127—135
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Fariborz Ghaffarpasand,1 Saeed Torabi,2 Ali Rasti,3 Mohammad Hadi Niakan,4 Sara Aghabaklou,5 Fatemeh Pakzad,6 Maryam Sadat Beheshtian,7 Reza Tabrizi8
1Research Center for Neuromodulation and Pain, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Anesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany; 3Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 4Trauma Research Center, Rajaei Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran; 5Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran; 6Department of Anesthesiology, Shiraz University of Medical Sciences, Shiraz, Iran; 7Department of Neurosurgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 8Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
Background: Traumatic brain injury (TBI) remains a main public health problem being associated with high mortality and morbidity. The functional outcome of TBI remains unfavorable despite several surgical and medical therapies. Cerebrolysin is a neuropeptide with potential neuroregenerative entities.
Objective: The aim of the current systematic review and meta-analysis was to investigate the effects of cerebrolysin on functional outcome in patients with moderate and severe TBI.
Data sources: Online databases used included Medline, Scopus, EMBASE, Google Scholar, Web of Science, and Cochrane Library.
Study eligibility criteria: All the relevant studies with randomized clinical trial and cohort design evaluating the effects of intravenous cerebrolysin vs placebo on functional outcome of patients with TBI within the English literature up to October 2018 were included.
Study appraisal and synthesis methods: The articles were reviewed by two independent authors and the data were extracted to a data sheet. I2 and Cochran’s Q-statistics were used to assess heterogeneity. Based on the presence of significant heterogeneity across included studies, data were pooled using random-effects model with Dersimonian–Laird method and presented as standardized mean differences (SMDs) and corresponding 95% CI.
Results: Five articles (5,685 participants) were included in the current meta-analysis. The overall pooled findings using random-effects models among patients with TBI indicated that intravenous administration of cerebrolysin significantly increased Glasgow Outcome Scale score (SMD =0.30; 95% CI: 0.18 to 0.42; P<0.001; I2: 87.8%) and decreased modified Rankin Scale score (SMD =-0.29; 95% CI: -0.42 to 0.16; P=0.05; I2: 89.6%).
Limitations: The results are mainly based on cohort studies and there is a lack of clinical trials in the literature. There is also heterogeneity among the studies regarding the dosage and duration of administration and the measurement of functional outcome.
Conclusion: The results of the current study revealed that intravenous administration of cerebrolysin is associated with improved functional outcome in patients with TBI measured by the Glasgow Outcome Scale and the modified Rankin Scale scores.
Keywords: traumatic brain injury, TBI, cerebrolysin, functional outcome, Glasgow Coma Scale, GOS, modified Rankin Scale, mRS
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]